Insights

Pro Medicus (ASX:PME) share price jumps after FY21 result

Investors are buying up Pro Medicus shares today after its FY21 results…
The post Pro Medicus (ASX:PME) share price jumps after FY21 result appeared first on The Motley Fool Australia. –

The Pro Medicus Limited (ASX: PME) share price is moving higher in early trade on Wednesday. This follows the healthcare imaging company releasing its full-year results for FY21.

At the time of writing, Pro Medicus shares are fetching $58.42 apiece, up 3.4%.

Pro Medicus share price rises on

Revenue from customers increased 19.5% to $67.9 million
Underlying profit before tax up 41% to $42.6 million compared to prior year
Net profit after tax attributable to shareholders increased 33.7% to $30.9 million
Fully franked final dividend of 8 cents per share declared, taking total dividends in FY21 to 15 cents per share
Record number of new contracts announced during the year
Company remains debt free, increasing cash and other financial assets to $61.8 million, up 42.4%

What happened in FY21 for Pro Medicus

It was another record financial year for the healthcare imaging company valued at a $5.98 billion market capitalisation. Pro Medicus was undeterred by the pandemic, delivering a significant 19.5% increase in revenue from customer contracts — taking the total to $67.9 million.

During the year, sales and implementations initiatives were at an all-time high, demonstrating the minimal impact COVID-19 restrictions had on the business. This enabled the company to cement several milestone contracts in FY21. Some of these include the $25 million 7 year deal with NYU Langone Health and the $40 million 7 year contract with Intermountain Healthcare.

Despite significant currency fluctuations, Pro Medicus’ bottom-line earnings came in at $30.9 million — representing an increase of 33.7% on the previous year.

The significant uptick in profit has allowed the board to declare a fully franked final dividend of 8 cents per share. This takes total FY21 dividends to 15 cents per share, giving an indicative yield of 0.26%.

What did management say?

Commenting on the result, Pro Medicus Chief Executive Officer Dr Sam Hupert said:

It was our most successful year by any measure. All of our key financial metrics headed in the right direction. We foreshadowed a step-up in revenue this year despite currency headwinds and lower numbers in the first quarter due to COVID restrictions and we have delivered on that. Margins continued to increase as did our cash and other financial assets. It was also our biggest year in terms of both sales and implementations, laying the
foundation for a further step-up in exam volumes in FY22

Additionally, regarding the company’s pipeline potential, Mr Hupert said:

Although we had a record year in terms of new contracts, our pipeline remains very healthy both in terms of quality and quantity. There is a good mix across the spectrum of opportunities; some cloud, some on-premise, some academic and some in the non-academic-IDN space as well as in the for-profit and private sector.

What’s next for Pro Medicus?

Pro Medicus did not specify any outlook or guidance for FY22. However, the company remains focused on expanding its customers through its pipeline. Notably, a number of opportunities are for more than one Visage product.

Additionally, Pro Medicus continues to develop products with its AI Accelerator program.

Pro Medicus share price snapshot

The Pro Medicus share price has returned an impressive 131% to shareholders over the past year. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) has climbed 22.8% during the same time frame.

Based on the current share price, Pro Medicus is trading on a 194 times price-to-earnings (P/E) ratio.

The post Pro Medicus (ASX:PME) share price jumps after FY21 result appeared first on The Motley Fool Australia.

Should you invest $1,000 in Pro Medicus right now?

Before you consider Pro Medicus, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

How did the Pro Medicus (ASX:PME) share price respond last earnings season?
The best and worst performing ASX 200 healthcare shares of 2021

Pro Medicus (ASX:PME) share price tumbles 5% on broker downgrade
Why Fortescue, Over The Wire, Pro Medicus, & Whispir shares are dropping

ASX 200 midday update: Afterpay to be acquired by Square, Oil Search to merge with Santos

Motley Fool contributor Mitchell Lawler owns shares of Pro Medicus Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!